Literature DB >> 7022279

Estrogen replacement therapy.

H L Judd, R E Cleary, W T Creasman, D C Figge, N Kase, Z Rosenwaks, G E Tagatz.   

Abstract

The use of estrogen replacement therapy in postmenopausal women is under close scrutiny. The indications and side effects of replacement therapy are reviewed, and recommendations regarding its use are made. Hot flashes, atrophy of the vaginal epithelium, and prevention of osteoporosis have been established as indications for estrogen replacement therapy. Prevention of cardiovascular disease, aging changes of skin, and the occurrence of mental illness have also been suggested as indications, but beneficial effects of estrogen replacement therapy for these problems have not been clearly established. Studies have shown that side effects of estrogen replacement therapy include endometrial cancer, hypertension, gallbladder disease, and angina pectoris. Breast cancer may also be a risk factor, but a consensus of opinion has not been established. Pulmonary embolism, cerebral vascular accident, or myocardial infarction has not been associated with estrogen replacement therapy. The use of progesterone with estrogen replacement therapy has been shown to reduce the occurrence rate of endometrial carcinoma, but it does not prevent all the actions of estrogen. Oral administration of estrogen is the preferred route despite misgivings about portal absorption and liver metabolism. Further studies must examine this question. Various agents have been shown to be effective in treating some climacteric symptoms. These include progesterone for hot flashes and calcium for the prevention of osteoporosis. Other agents may also be effective but have not been tested critically.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7022279

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  8 in total

1.  Obstetrics and gynecology-important advances in clinical medicine: comparative risks of osteoporosis and endometrial cancer.

Authors:  B J Davidson
Journal:  West J Med       Date:  1983-10

2.  Therapeutic Issues in Turner's Syndrome.

Authors:  F A Conte; M M Grumbach
Journal:  West J Med       Date:  1982-07

Review 3.  Pharmacokinetic considerations in the use of newer transdermal formulations.

Authors:  G Ridout; G C Santus; R H Guy
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

4.  Guidelines for community menopausal clinics.

Authors:  G M Craig
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-25

Review 5.  Postmenopausal osteoporosis.

Authors:  J C Stevenson; M I Whitehead
Journal:  Br Med J (Clin Res Ed)       Date:  1982 Aug 28-Sep 4

6.  Changes in aquaporin (AQP)2 and AQP3 expression in ovariectomized rat urinary bladder: potential implication of water permeability in urinary bladder.

Authors:  Sun-Ouck Kim; Seung Hee Song; Eu Chang Hwang; Kyung Jin Oh; Kyuyoun Ahn; Seung Il Jung; Taek Won Kang; Dongdeuk Kwon; Kwangsung Park; Soo Bang Ryu
Journal:  World J Urol       Date:  2011-04-11       Impact factor: 4.226

Review 7.  Re-appraising the potential of naringin for natural, novel orthopedic biotherapies.

Authors:  Kristin E Yu; Kareme D Alder; Montana T Morris; Alana M Munger; Inkyu Lee; Sean V Cahill; Hyuk-Kwon Kwon; JungHo Back; Francis Y Lee
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-08       Impact factor: 5.346

8.  Enhancement of BDNF concentration and restoration of the hypothalamic-pituitary-adrenal axis accompany reduced depressive-like behaviour in stressed ovariectomised rats treated with either Tualang honey or estrogen.

Authors:  Badriya Al-Rahbi; Rahimah Zakaria; Zahiruddin Othman; Asma' Hassan; Asma Hayati Ahmad
Journal:  ScientificWorldJournal       Date:  2014-01-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.